Furthermore, in patients with EBV+ posttransplant lymphoproliferative disorders (PTLD), latency II or III profiles were strongly associated with PDL1 expression in tumor associated macrophages (TAMs) compared with EBV− cases, and also with cases expressing latency I [92], suggesting that latency II and III viral genes, such as LMP1, could be involved in PDL1 upregulation. The gene discussed is CD274; the disease is neoplasm.